|Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma|
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
|Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study|
B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ...
Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998
|Phase II study of the efficacy and safety of pembrolizumab for relapsed/refractory classic Hodgkin lymphoma|
R Chen, PL Zinzani, MA Fanale, P Armand, NA Johnson, P Brice, ...
Journal of Clinical Oncology 35 (19), 2125, 2017
|Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma|
J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ...
New England Journal of Medicine 372 (17), 1598-1607, 2015
|Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma|
P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ...
New England Journal of Medicine 374 (25), 2419-2429, 2016
|Brentuximab vedotin with chemotherapy for stage III or IV Hodgkin’s lymphoma|
JM Connors, W Jurczak, DJ Straus, SM Ansell, WS Kim, A Gallamini, ...
New England Journal of Medicine 378 (4), 331-344, 2018
|Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of …|
D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ...
The Lancet 381 (9880), 1817-1826, 2013
|European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma …|
JM Foran, AZ Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ...
Journal of Clinical Oncology 18 (2), 317-324, 2000
|Granulocyte colony-stimulating factor to prevent dose-limiting neutropenia in non-Hodgkin's lymphoma: a randomized controlled trial|
R Pettengell, H Gurney, JA Radford, DP Deakin, R James, PM Wilkinson, ...
|Phase III trial of consolidation therapy with yttrium-90–ibritumomab tiuxetan compared with no additional therapy after first remission in advanced follicular lymphoma|
F Morschhauser, J Radford, A Van Hoof, U Vitolo, P Soubeyran, H Tilly, ...
Journal of Clinical Oncology 26 (32), 5156-5164, 2008
|Myocardial infarction mortality risk after treatment for Hodgkin disease: a collaborative British cohort study|
AJ Swerdlow, CD Higgins, P Smith, D Cunningham, BW Hancock, ...
Journal of the National Cancer Institute 99 (3), 206-214, 2007
|Phase II study of ET-743 in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial|
A Le Cesne, JY Blay, I Judson, A Van Oosterom, J Verweij, J Radford, ...
Journal of Clinical Oncology 23 (3), 576-584, 2005
|Imatinib mesylate (STI-571 Glivec®, Gleevec™) is an active agent for gastrointestinal stromal tumours, but does not yield responses in other soft-tissue sarcomas that are …|
J Verweij, A van Oosterom, JY Blay, I Judson, S Rodenhuis, ...
European Journal of Cancer 39 (14), 2006-2011, 2003
|Orthotopic reimplantation of cryopreserved ovarian cortical strips after high-dose chemotherapy for Hodgkin's lymphoma|
JA Radford, BA Lieberman, DR Brison, ARB Smith, JD Critchlow, ...
The Lancet 357 (9263), 1172-1175, 2001
|Multicenter phase II study of iodine-131 tositumomab for chemotherapy-relapsed/refractory low-grade and transformed low-grade B-cell non-Hodgkin’s lymphomas|
JM Vose, RL Wahl, M Saleh, AZ Rohatiner, SJ Knox, JA Radford, ...
Journal of clinical oncology 18 (6), 1316-1323, 2000
|Randomised phase II trial of pegylated liposomal doxorubicin (DOXIL®/CAELYX®) versus doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study by the …|
I Judson, JA Radford, M Harris, JY Blay, Q van Hoesel, A Le Cesne, ...
European Journal of Cancer 37 (7), 870-877, 2001
|Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results|
ML Wang, KA Blum, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
Blood, The Journal of the American Society of Hematology 126 (6), 739-745, 2015
|International consensus conference on high-dose therapy with hematopoietic stem cell transplantation in aggressive non-Hodgkin's lymphomas: report of the jury|
MA Shipp, MD Abeloff, KH Antman, G Carroll, A Hagenbeek, M Loeffler, ...
Journal of Clinical Oncology 17 (1), 423-423, 1999
|How can we improve our understanding of cardiovascular safety liabilities to develop safer medicines?|
HG Laverty, C Benson, EJ Cartwright, MJ Cross, C Garland, T Hammond, ...
British journal of pharmacology 163 (4), 675-693, 2011
|Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma|
SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ...
European journal of nuclear medicine and molecular imaging 37, 1824-1833, 2010